Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions
Gambhir, D.S.; Mukhopadhyay, S.
Indian Heart Journal 52(5): 524-532
2000
ISSN/ISBN: 0019-4832 PMID: 11256774 Document Number: 514560
Document emailed within 1 workday
Related Documents
Zimarino, M.; De Caterina, R. 2004: Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit Journal of Cardiovascular Pharmacology 43(3): 325-332Adelman, A.G.; Caramori, P.R.; Cohen, E.A.; Chisholm, R.J.; Côté, G.; Ducas, J.; O'Neill, B.J.; Tcheng, J.E. 1998: The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era Canadian Journal of Cardiology 14(8): 1057-1066
Moliterno, D.J.; Topol, E.J. 1997: Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction Thrombosis and Haemostasis 78(1): 214-219
Quinn, M.J.; Moliterno, D.J. 2002: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes Minerva Cardioangiologica 50(5): 547-553
Kitagawa, H.; Yamamoto, N.; Yamamoto, K.; Tanoue, K.; Kosaki, G.; Yamazaki, H. 1989: Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells Cancer Research 49(3): 537-541
Cantor, W.J.; Madan, M.; O'Shea, J.C.; Chisholm, R.J.; Lui, H.K.; Cohen, D.J.; Feldman, R.L.; Green, R.; Hellkamp, A.S.; Kitt, M.M.; Tcheng, J.E. 2005: Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial Journal of Invasive Cardiology 17(7): 360-364
Kereiakes, D.J.; Kleiman, N.; Ferguson, J.J.; Runyon, J.P.; Broderick, T.M.; Higby, N.A.; Martin, L.H.; Hantsbarger, G.; McDonald, S.; Anders, R.J. 1997: Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment Circulation 96(4): 1117-1121
Cook, N.S.; Bruttger, O.; Pally, C.; Hagenbach, A. 1993: The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active Thrombosis and Haemostasis 70(5): 838-847
Kassam, S.; Cantor, W.J.; Patel, D.; Gilchrist, I.C.; Winegard, L.D.; Rea, M.E.; Bowman, K.A.; Chisholm, R.J.; Strauss, B.H. 2004: Radial versus femoral access for rescue percutaneous coronary intervention with adjuvant glycoprotein IIb/IIIa inhibitor use Canadian Journal of Cardiology 20(14): 1439-1442
White, H.D. 2000: Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? Journal of Invasive Cardiology 12 Suppl A: 6a
Abu-Amero, K.K.; Wyngaard, C.A.; Dzimiri, N. 2004: Association of the platelet glycoprotein receptor IIIa (PlA1/PlA1) genotype with coronary artery disease in Arabs Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 15(1): 77-79
Cohen, M. 2000: Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes Journal of Invasive Cardiology 12 Suppl E: E5
Mak, K.H.; Kottke-Marchant, K.; Brooks, L.M.; Topol, E.J. 1998: In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia Thrombosis and Haemostasis 80(6): 989-993
Müller, T.H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J. 1997: Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men Circulation 96(4): 1130-1138
Kessler, S.; Kessler, D.; Frishman, W.H. 1999: Antiplatelet therapy: glycoprotein IIb/IIIa receptor antagonists Drugs of Today 35(6): 413-418
Kondo, K. 2000: Investigational new drugs among glycoprotein IIb/IIIa-receptor antagonists Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 116(5): 263-268
Singh, S.; Gopal, A.K.; Bahl, V.K. 2005: Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence Indian Heart Journal 57(3): 201-209
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Preobrazhenskiĭ, D.V. 2011: New platelet P2Y12 inhibitors versus clopidogrel in percutaneous coronary interventions. a meta-analysis Kardiologiia 51(2): 70-71
Fujimoto, T.; Fujimura, K.; Kuramoto, A. 1990: Role of membrane glycoprotein (GP) IIb-IIIa complex on platelet Ca2+ ion influx Rinsho Byori. Japanese Journal of Clinical Pathology Suppl 86: 34-43